INTRODUCTION

N-Glycosylation sequons of proteins (Asn-Xaa-Ser/Thr, where Xaa is any amino acid except proline) typically carry a diverse repertoire of structures, called glycan microheterogeneity. The diversity of protein glycosylation is influenced by the activity of many enzymes involved in the N-glycan biosynthetic machinery. The source and the location of the glycoproteins also strongly influence the final glycan structure and site specificity. Microheterogeneity of protein N-glycoforms changes significantly in cancer diseases often in connection with changes in the activity of enzymes involved in N-glycoprotein synthesis. One of the best documented examples of aberrant glycosylation is the progression of liver disease to hepatocellular carcinoma (HCC). In the case of liver disease, changes in protein N-glycosylation can be analyzed efficiently by serologic monitoring of liver-secreted glycoproteins. Reported changes of N-glycan repertoire in cancer include the formation of bisecting glycans with one molecule of N-acetylgalactosamine attached via β1−4 bond to the branched core mannose, asialo and agalacto glycans, truncated structures with terminal galactoses or N-acetylgalactosamines, (poly-)N-acetylactosamines with beta 1−6 branching, and fucosylated glycans with fucose attached mainly at the C-3 position of outer arm N-acetylglucosamine or less frequently at the C-6 N-acetylgalactosamine of the N-glycan core.

We have previously detected multiply outer arm fucosylated glycoforms of haptoglobin (Hp) in the context of HCC. We have now isolated three additional glycopeptides from serum of a patient that carries hyper-fucosylated Hp (up to six fucoses per glycan). These liver-secreted glycopeptides copurify on hemin agarose and include hemopexin (Hpx), kininogen-1 (Kng-1), and complement factor H, where core fucosylation of the bi-antennary glycans on select glycopeptides reaches 15−20% intensity. These protein-specific differences in fucosylation, observed in proteins isolated from the same patient source, suggest that factors other than up-regulation of enzymatic activity regulate the microheterogeneity of glycoforms. This has implications for selection of candidate proteins for disease monitoring and suggests that site-specific glycoforms have structural determinants, which could lead to functional consequences for specific subsets of proteins or their domains.

KEYWORDS: mass spectrometry, exoglycosidase treatment, microheterogeneity, N-glycans, permethylation, MSn structural analysis, glycopeptides, hepatocellular carcinoma, fucosylation, site specificity

ABSTRACT: Chronic liver diseases are a serious health problem worldwide. One of the frequently reported glycan alterations in liver disease is aberrant fucosylation, which was suggested as a marker for noninvasive serologic monitoring. We present a case study that compares site specific glycoforms of four proteins including haptoglobin, complement factor H, kininogen-1, and hemopexin isolated from the same patient. Our exoglycosidase-assisted LC−MS/MS analysis confirms the high degree of fucosylation of some of the proteins but shows that microheterogeneity is protein- and site-specific. MSn analysis of permethylated detached glycans confirms the presence of LeY glycoforms on haptoglobin, which cannot be detected in hemopexin or complement factor H; all three proteins carry Lewis and H epitopes. Core fucosylation is detectable in only trace amounts in haptoglobin but with confidence on hemopexin and complement factor H, where core fucosylation of the bi-antennary glycans on select glycopeptides reaches 15−20% intensity. These protein-specific differences in fucosylation, observed in proteins isolated from the same patient source, suggest that factors other than up-regulation of enzymatic activity regulate the microheterogeneity of glycoforms. This has implications for selection of candidate proteins for disease monitoring and suggests that site-specific glycoforms have structural determinants, which could lead to functional consequences for specific subsets of proteins or their domains.

KEYWORDS: mass spectrometry, exoglycosidase treatment, microheterogeneity, N-glycans, permethylation, MSn structural analysis, glycopeptides, hepatocellular carcinoma, fucosylation, site specificity
and complement factor H (CFH). Our assumption is that the same glycosylation machinery that hyper-fucosylates Hp would lead to hyper-fucosylation of additional proteins. We report the analysis of the distribution of N-glycans between the four proteins and on specific glycopeptides using two complementary analytical methods. We have used sialidase-assisted tandem mass spectrometry of glycopeptides to study the site-specific protein glycoforms and further determined by ESI-ITMSn the analysis of permethylated glycans detached from each of the purified proteins. This is to our knowledge the first case report of detailed structural characterization of site-specific glycoforms of proteins isolated directly from patient serum.

**EXPERIMENTAL SECTION**

**Patient Samples**

Proteins were isolated from serum of a patient previously shown to carry multiply fucosylated glycoforms of Hp. This patient was enrolled under protocols approved by the Georgetown University Institutional Review Board in collaboration with the Georgetown University Hospital, Department of Hepatology and Liver Transplantation, Washington, DC. The patient is a 61 year old Caucasian male, blood group O, diagnosed by the attending physician as a cirrhotic patient of HCV etiology with HCC stage T2N0M0, according to the seventh edition of the American Joint Committee on Cancer Staging manual.

**Isolation of Glycoproteins from Human Plasma**

Hp was isolated as described elsewhere. Hpx, Kng-1, and CFH were isolated by incubation of 500 μL of human plasma with 400 μL of heme-agarose beads (Sigma Aldrich, St. Louis, MO) at 4 °C overnight. After the incubation, the resin was washed with 10 mL of PBS buffer, and bound glycoproteins were released by the addition of 500 μL of 0.2 M citric acid, pH 2 and immediately neutralized by 270 μL of 1 M Tris/Cl buffer, pH 9. Proteins were further separated by reversed-phase chromatography using C18 macroporous mRP Hi-recovery protein column (50 mm, 75 μm, 50 mm, 150 mm, 75 μm ID × 150 mm, Waters) coupled to a QStar Elite mass spectrometer (Applied Biosystems, Foster City, CA). Two picomoles of each glycoprotein digest were separated at a flow rate of 0.4 μL/min, using the following gradient: 0 min 1% B, 35 min 35% B, 37 min 90% B, 42 min 90% B, 44 min 1% B, 55 min 1% B (Solvent A: 0.1% formic acid in 2% ACN; Solvent B: 0.1% formic acid in 98% ACN). The mass spectrometer was operated in data-dependent mode; after the full-scan (m/z 400 to m/z 1800) survey, the three most intense precursor ions were selected for collision-induced dissociation. Collision energy and MS/MS accumulation time were set automatically, and the MS/MS spectra were recorded from m/z 150 to m/z 2000. Dynamic exclusion was set at 15 s and five counts for two repeated precursors. Fragment intensity multiplier was set at 16 with maximum accumulation 2 s, which resulted in a total cycle time of 6.5 s.

**Structural Characterization of Detached Glycans**

Hp, Hpx, and CFH purified as previously described (50 μg each) were enzymatically deglycosylated with N-glycanase at 37 °C overnight (Prozyme, Hayward, CA). Released N-glycans were purified by C18 and porous graphitized carbon solid-phase extraction steps as described previously. Briefly, N-glycans were reduced using borane-ammonia and permethylated using spin columns, as previously described.

MALDI-ToF analysis was performed on a Shimadzu Kratos Axima-CFR (Columbia, MD) using DHB as a matrix. This step provided a survey of the compositions present in each sample. Detailed mass spectrometric analysis was performed on a Thermo LTQ (San Jose, CA) mass analyzer equipped with an Advion Triversa Nanomate (Ithaca, NY). Samples were dissolved in 1:1 methanol/water for direct infusion into the LTQ. All ions were sodium adducts, and select fucosylated compositions were disassembled to determine detailed structure as described.

**Data Interpretation**

LC−MS/MS of glycopeptides: Analyst QS 2.0 software (Applied Biosystems, Foster City, CA) was used to process MS data sets, and glycoproteins were identified by Mascot search engine. Protein sequences were downloaded from UniProt database. MS/MS spectra were converted to mzXML format using mzconvert from the ProteoWizard project. GlycoPeptideSearch (GPS) engine was used for finding of glycopeptides forms for each glycoprotein. Identified glycopeptides were further confirmed by manual data inspection. We adopt the N-glycan nomenclature from the NIBRT GlycoBase databases. Peak area counts from extracted ion chromatogram (XIC) of the precursor ion of each identified glycoform were used for calculation of percentage distribution of glycopeptides and also for calculation of ratio between fucosylated and nonfucosylated glycoforms. All samples were analyzed in triplicate.

**RESULTS AND DISCUSSION**

Our recent analysis of Hp isolated from serum of a patient with HCC detected multiply fucosylated glycans with up to six...
We have used glycosidase assisted LC−MS/MS to show the presence of Lewis Y type glycoforms on one glycopeptide of Hp. In this study, we use the recently optimized glycosidase-assisted LC−MS/MS methods and MSn structural analysis of detached N-glycans to compare glycoforms of Hp with glycoforms of Hpx, Kng-1, and CFH isolated from plasma of the same patient. Our goal is to compare site-specific microheterogeneity of proteins synthesized by the same

**Table 1. List of Identified Glycoforms of Hp, Kng-1, Hpx, and CFH and Their Intensity Distribution at All Identified Glycopeptides Determined after Neuraminidase Treatment**

| Glycopeptide (AA position) | Glycoform | % | Observed m/z (Charge) | Glycopeptide (AA position) | Glycoform | % | Observed m/z (Charge) |
|----------------------------|-----------|---|----------------------|----------------------------|-----------|---|----------------------|
| Leu-56-Asp-57               | A2G2      | 11 | 1012.7 (+)           | SWP-104                  | A2G2      | 84 | 1009.7 (+)           |
|                            | A3G3      | 39 | 851.1 (+)            |                            | A2G2F1    | 4  | 1058.5 (+)           |
|                            | A3G3F1    | 50 | 887.6 (+)            | A2G2F2                  | 3  | 1113.4 (+)           |
|                            | A2G2      | 22 | 1018.7 (+)           | A3G3F1                  | 6  | 1180.2 (+)           |
|                            | A2G2F1    | 1  | 1087.5 (+)           | A3G3F2                  | 1  | 1228.8 (+)           |
|                            | A2G3      | 23 | 855.6 (+)            | A44F1                   | <1 | 684.0 (+)            |
|                            | A3G3F1    | 42 | 992.1 (+)            | A44F1F1                 | 1  | 976.9 (+)            |
|                            | A3G3F2    | 11 | 928.6 (+)            | A44F2                   | 1  | 1013.2 (+)           |
|                            | A4G4      | 2  | 1143.9 (+)           |                            | A4G4F3    | <1 | 1049.7 (+)           |
|                            | A4G4F4    | 2  | 1173.1 (+)           |                            | A4G4F5    | <1 | 1202.7 (+)           |

**Haptoglobin**

| Glycopeptide (AA position) | Glycoform | % | Observed m/z (Charge) | Glycopeptide (AA position) | Glycoform | % | Observed m/z (Charge) |
|----------------------------|-----------|---|----------------------|----------------------------|-----------|---|----------------------|
| Val-35-Leu-41              | A2G2      | 30 | 855.1 (+)            |                            | A2G2F1    | 1  | 1065.1 (+)           |
|                            | A2G2F1    | <1 | 891.6 (+)            | A2G2F2                  | 17 | 1062.1 (+)           |
|                            | A2G2F2    | 15 | 948.4 (+)            | A2G2F3                  | 13 | 889.1 (+)            |
|                            | A3G3F1    | 21 | 1092.4 (+)           | A3G3F2                  | 19 | 924.6 (+)            |
|                            | A3G3F2    | 4  | 1094.4 (+)           | A3G3F3                  | 2  | 961.1 (+)            |
|                            | A3G3F3    | <1 | 1055.9 (+)           | A3G3F4                  | 70 | 911.7 (+)            |
|                            | A3G4      | 5  | 1037.6 (+)           | A4G4F1                  | 17 | 846.2 (+)            |
|                            | A4G4F2    | 7  | 1074.2 (+)           | A4G4F3                  | 1  | 1076.0 (+)           |
|                            | A4G4F4    | 11 | 1183.7 (+)           | A4G4F5                  | 1  | 1202.0 (+)           |
|                            | A4G4F6    | <1 | 1202.0 (+)           |                            | A4G4F7    | 1  | 1268.6 (+)           |
|                            | A4G4F8    | 1  | 1266.8 (+)           |                            | A4G4F9    | <1 | 1304.9 (+)           |
|                            | A4G4F10   | 74 | 1076.2 (+)           |                            | A4G4F11   | 1  | 1319.0 (+)           |
|                            | A4G4F12   | 3  | 1112.7 (+)           |                            | A4G4F13   | 7  | 1171.4 (+)           |
|                            | A4G4F14   | 15 | 1240.0 (+)           |                            | A4G4F15   | 1  | 1252.5 (+)           |
|                            | A4G4F16   | 1  | 1254.5 (+)           |                            | A4G4F17   | 2  | 1298.8 (+)           |
|                            | A4G4F18   | <1 | 1258.7 (+)           |                            | A4G4F19   | 2  | 1299.5 (+)           |
|                            | A4G4F20   | <1 | 1320.1 (+)           |                            | A4G4F21   | 3  | 1322.2 (+)           |
|                            | A4G4F22   | <1 | 1388.2 (+)           |                            | A4G4F23   | 1  | 1351.4 (+)           |
|                            | A4G4F24   | <1 | 1388.2 (+)           |                            | A4G4F25   | 1  | 1415.6 (+)           |
|                            | A4G4F26   | 1  | 1437.9 (+)           |                            | A4G4F27   | 1  | 1474.6 (+)           |
|                            | A4G4F28   | 27 | 1304.9 (+)           |                            | A4G4F29   | 1  | 1498.8 (+)           |

**Figure 1.** UV detection (214 nm) of a glycoprotein complex isolated by heme-agarose affinity chromatography and separated by reversed-phase chromatography. Peaks containing the proteins of interest are numbered as follows: 1-CFH, 2-Kng-1, and 3-Hpx.

**Table 1.** List of Identified Glycoforms of Hp, Kng-1, Hpx, and CFH and Their Intensity Distribution at All Identified Glycopeptides Determined after Neuraminidase Treatment

"Glycan abbreviations are adopted from the NIBRT GlycoBase databases (A2G2, bi-antennary glycan terminated with two galactoses; A3G3, tri-antennary glycan terminated with three galactoses, etc.; F, fucose; we do not resolve core and outer arm)."
enzymatic machinery and under the same pathophysiological conditions. The proteins were purified by reversed-phase chromatography after incubation of the patient’s plasma with heme-agarose beads. Isolation of these proteins as a complex on heme-agarose is expected because all three proteins have high affinity for either heme or each other.27 Because N-glycans have minimal interaction with the reversed-phase resin, all glycoforms of the protein coelute and their microheterogeneity can be analyzed efficiently in the isolated protein. Hpx and CFH were further dissociated (MS3) and product ion at m/z 646 (derived from 834 fragment) was further collided (MS5). MSn analysis shows at least three possible isomers at this composition, with both core and antennal fucosylation. Figure 2 shows selected MSn spectra for the reduced and permethylated tetra-antennary, disialylated, and doubly fucosylated composition (m/z 1366 (3+)). Figure 2A shows the MS2 spectrum of this composition, with insets displaying zoomed in views of the terminal (B2) and internal (B3/Y) lactosamine fragments as well as the Y1 fragment (m/z 490) indicative of the fucosylated reducing-end GlcNAc; the second inset shows the terminal doubly fucosylated lactosamine (m/z 834) and the sialylated lactosamine (m/z 847) fragments. The m/z 490 fragment indicates traces of core fucosylated glycans. The MS2 spectrum also clearly indicates two different antennal fucosylation fragments: the terminal (B-type) monofucosylated fragment at m/z 660 and the terminal (B-type) difucosylated fragment at m/z 834. Both fragments were further dissociated (MS5) and product ion at m/z 646 (derived from 834 fragment) was further collided (MS5). MSn structural analysis of the MS/MS spectrum is standardized such that all diagnostic fragments are in the same LC-MS/MS analysis; MSn fragmentation is a complementary method that resolves the linkage efficiently. The specific diagnostic fragments are the m/z 259, a C-type terminal hexose that can arise from a Lewis X structure but not an H2 structure, m/z 329, a sialylated cleavage fragment that can only arise from Lewis X, not H2 or Lewis A, and the m/z 503, another sialylated cleavage fragment which can only arise from H2, not H1 or Lewis A or X. Detailed structures with fragment identifications are in the Supporting Information. The low-intensity fragment at m/z 834 (terminal difucosylated lactosamine) in the MS/MS spectrum is

Figure 2. Structural analysis of permethylated tetra-antennary doubly fucosylated glycan (m/z 1366 (3+)) from Hpt by MSn fragmentation. Spectrum A shows the MS2 spectrum with zoomed-in views of the core fuc-GlcNAc (Y1, m/z 490) and Lewis Y (m/z 834) fragments. Panel B shows the MS3 spectrum of m/z 660, showing a mixture of Lewis X and H2 structures. Panels C and D show MS3 and MS4 spectra, respectively, of the Lewis Y epitope disassembly. Antenna localization was not empirically determined.
consistent with the possible Lewis Y epitope. Disassembly of this ion through MS3, m/z 834 (Figure 2C) and MS4, m/z 834 → 646 (Figure 2D) are consistent with the Lewis Y epitope. The MS3 and MS4 spectra both contain the m/z 503 fragment, a 3,5-A cross-ring cleavage ion, of the same structure as that found in H2, which distinguishes this from Lewis B. Because this fragment is of the same structure as that from H2, the fragmentation pathway, through the m/z 834 ion, is of great importance in assigning this structure.

We were not able to detect any core-fucosylated glycoforms in Hp by LC–MS/MS. The low abundant core-fucosylated glycoform detected by MSn (see above) is either a minor component below the detection limit of our LC–MS/MS analysis or derives from a trace-contaminating protein. We cannot exclude that low percentage of core fucose exists especially on the doubly fucosylated site, but it is clear that core-fucosylated glycoforms represent at most a very minor component of the Hp glycoforms.

Hemopexin: Hpx is a heme-binding 60 kDa plasma glycoprotein containing five N-glycosylation sites and one N-terminal O-glycosylation site. Its major biological role is defense against hemoglobin-mediated oxidative damage during intra-

Figure 3. (A) MS profile of Kng-1 peptide HGIQYFNNNTQHSSLFMLNEVKR bearing tetra-antennary glycans with up to five fucoses. (B) CID spectrum of tetra-antennary triply fucosylated HGIQYFNNNTQHSSLFMLNEVKR glycopeptide with oxonium ions corresponding to GlcNAc and GlcNAc-Hex fragments (m/z 204 and 366) and GlcNAc-Gal-Fuc fragment (m/z 512) consistent with Lewis X structure.
vascular hemolysis.\textsuperscript{28} We have analyzed microheterogeneity of three tryptic N-glycopeptides of Hpx. Each glycopeptide is occupied by complex glycans, primarily bi- and tri-antennary glycoforms with up to two fucoses. Bi-antennary glycans dominate, and their fucosylated counterparts represent a minor (<10%) contribution (Table 1). One tetra-antennary glycoform with three fucoses was observed at SWPAVGNCSSALR peptide, but multiply fucosylated and highly branched structures are rare on Hpx, contrary to Hp. Although the ion intensities of most singly fucosylated bi-antennary glycopeptides were not sufficient for fragmentation, the measurable CID spectra contain low-intensity peptide-HexNAc-Fuc fragment consistent with core fucosylation. The presence of oxonium ions at \( m/z \) 512.2 indicates the presence of outer-arm fucose. The intensity of fragments, which could distinguish fucose linkage in doubly and triply fucosylated glycoforms, was under the detection limit of our instrument. Fragmentation spectra of SWPAVGNCSSALR glycopeptide bearing A3G3F1 and A3G3F2 glycans contain both oxonium ion \( m/z \) 512.2 consistent with Lewis X type linkage. The presence of oxonium ion at \( m/z \) 658.2 in fragmentation spectrum of the A3G3F2 glycopeptide could suggest the presence of Lewis-Y-type structure, but rearrangement of fucose at outer arms is a likely event;\textsuperscript{29} independent methods would have to confirm such linkage assignment. We were not able to confirm Lewis Y linkage by MS\textsuperscript{n} analysis and conclude that core fucosylation is minor and below the limit of our detection in the tri-antennary structures.\textsuperscript{29} These assignments are quite consistent with analysis of N-glycans detached from Hpx in a study of cirrhotic and HCC patients.\textsuperscript{14} Debruyne et al. observed intense bi-antennary glycan with small contribution of fucosylation and minor tri- and tetra-antennary glycoforms compared with the dominant bi-antennary structure. The authors found that outer-arm fucosylated tri- and tetra-antennary glycans are increased in HCC compared with bi-antennary glycan without fucose and suggest that their ratio can be used as a diagnostic test for detection of HCC.

MALDI-ToF spectrum of glycans released from isolated Hpx is dominated by bi-antennary structures (Supplemental Figure 1 in the Supporting Information). Disassembly of a bi-antennary, monosialylated, monofucosylated composition shows a mixture of core fucosylation, Lewis X, and sialylated Lewis X-containing isomers (Supplemental Figure 4 in the Supporting Information).

Kininogen-1: Kng-1, a plasma glycoprotein of 644 amino acids, contains a heavy chain with four N-glycosylation sites.\textsuperscript{30,31} Serine proteases cleave from Kng-1 bradykinin, a nine amino acid peptide that regulates many biological processes including inflammation, angiogenesis, and cell migration.\textsuperscript{32} We have identified bi- and tri-antennary glycans and their fucosylated forms at three of four N-glycosylation sites of Kng-1. The glycopeptide YNSQNQSNNQFVLYR was observed only with single glycoform A2G2. However, the intensity of this peptide is very low, and we cannot exclude the presence of other glycoforms below the detection limit of our method. Two glycopeptides carry tri-antennary glycoforms with up to two fucoses per glycan; moreover, glycopeptide HGIQYFNNNAMILNEVKR carries tetra-antennary glycans with up to five fucoses (Figure 3A). This is similar to the multiply fucosylated glycoforms of Hp and in contrast with the limited fucosylation of glycoforms associated with Hpx and CFH. Figure 3B shows a representative CID fragmentation spectrum of triply fucosylated tetra-antennary glycoform of HGIQYFNNNQTHHSSLFMLNEVKR peptide with glycan fragments consistent with Lewis X structure at \( m/z \) 512.2. There is no evidence of core fucosylation in Kng-1 glycopeptides based on their CID fragmentation. Unfortunately, we were not able to complete MS\textsuperscript{n} structural analysis of Kng-1’s glycans because the protein was not available in sufficient amount and purity.

Complement factor H: CFH is a 140 kDa (without carbohydrate moiety) plasma glycoprotein that regulates enzymatic activity of complement C3.\textsuperscript{33} CFH has nine N-glycosylation sequons and is primarily secreted to plasma by the liver even though a membrane bound form exists as well.\textsuperscript{34} We
have detected seven glycopeptides in the tryptic digest of CFH which cover eight sequons (one peptide is doubly glycosylated). All peptides carry a limited variety of glycoforms of the complex type; high mannose or hybrid glycoforms were not detected. We have observed dominant bi-antennary glycoforms on all sequons except peptide L(528)-R(567), which carries more intense tri-antennary glycoforms. The bi-antennary glycoforms are singly fucosylated, but the intensity of the fucosylated glycoforms is somewhat higher (up to 20%) than for Hpx (<10%). Similar to Hpx, the singly fucosylated tri-antennary glycoforms tend to have higher intensity than their nonfucosylated counterparts. We have detected the minimal amount of doubly fucosylated glycoforms; tetra-antennary glycoforms and glycoforms with more than two fucoses were not detected (Table 2). Structural analysis of detached permethylated glycans uncovered the presence of core-fucosylated glycans represented by Fuc-GlcNAc fragment at m/z 490 (Supplemental Figure 3 in the Supporting Information). The intensity of this fragment is roughly similar to the fragment at m/z 660 corresponding to LeX epitope. This is in contrast with other analyzed singly fucosylated glycoforms from Hpx and Hp, where the 660 fragment was dominant, and the 490 fragment was small but detectable. These findings demonstrate that the process of glycan branching and fucosylation is site-specific and differs significantly between different glycoproteins isolated from the same patient.

CONCLUSIONS

Our aim was to examine whether hyper-fucosylation of Hp is associated with hyper-fucosylation of other proteins isolated from serum of the same HCC patient. Our analysis focused on fucosylation because we observe only complex N-glycans on all isolated proteins examined in this study and because we have previously observed hyper-fucosylated structures on Hp. Comparison of the protein and site-specific heterogeneity of the glycoforms shows interesting general trends. Distribution of fucosylated glycoforms is protein- and site-specific (Table 1). Bi-antennary glycan without fucose is typically the major glycoform observed. Singly fucosylated bi-antennary glycoforms are absent or low-intensity compared with the nonfucosylated bi-antennary forms in almost all studied glycoproteins. The highest intensity of bi-antennary glycoforms was found on CFH, where fucosylated glycoforms reach up to 20% ion intensity of the nonfucosylated glycoforms (Table 1). Singly fucosylated tri- and tetra-antennary glycoforms have higher intensity than their nonfucosylated forms (Table 2). Tri-antennary singly fucosylated glycans are the most intense glycoforms across virtually all identified tri-antennary glycopeptides. Tetra-antennary glycans are, in general, less abundant and observed on select glycopeptides only.

The distribution of multifucosylated tri- and tetra-antennary glycoforms differs by protein and peptide. Hyper-fucosylated glycoforms with more fucoses than arms were observed only in Hp (up to six fucoses per glycopeptide) and Kng-1 (five fucoses per glycopeptide). In contrast with Hp and Kng-1, we have detected at most two fucoses on three of eight glycopeptides of CFH and only one glycopeptide with three fucoses in the case of Hpx (A4G4F3 on SWPAGNCSSALR peptide). Structural analysis of detached permethylated glycans shows differences in level of core fucosylation between the glycoproteins. For example, in both Hp and Hpx, core fucosylation is less abundant compared with CFH. Furthermore, it was observed that doubly fucosylated glycoforms of Hp contain both LewisX and LewisY epitopes. This shows that factors other than up-regulated glycosyltransferases define how and which glycosite is fucosylated. The determinants of site-specific microheterogeneity are not entirely known to our knowledge, but it is expected that the types of mature glycoforms detectable in disease context depend not only on the activity of glycosyltransferases but also on sequence of their action, distribution of the synthesized glycoproteins, their stability and turnover, and also on protein structure.

N-Glycosylation is a cotranslational process that originates in the ER, but the N-glycan structures continue to mature on folded proteins in Golgi apparatus. The protein’s secondary and tertiary structure determines the interaction with binding partners and accessibility of glycosyltransferases responsible for fucosylation, sialylation, and branching. A recent study correlated structural attributes of the protein substrates with glycan microheterogeneity. The authors suggest that protein structure (e.g., solvent accessibility, protein size, and hydrophobic index) affects glycan microheterogeneity. This is in agreement with our observation that glycoproteins isolated from serum of the same patient are differentially fucosylated, although we assume that the repertoire of glycan biosynthetic machinery is the same for all of the glycoproteins being characterized. We cannot exclude the possibility that some glycoforms are selectively removed from circulation, but it is hard to believe that all tri- and tetra-antennary fucosylated glycoforms of CFH or Hp would be so efficiently eliminated. In addition, differences in site-specific distribution of glycoform on each protein support influence of other factors (Table 1). For example, Kng-1 glycopeptide Y(44)-R(58) carries only one bi-antennary glycan compared with the tetra-antennary multiply fucosylated glycans on the neighboring peptide. It is more likely that the selection process is defined by local structure-recognition, which regulates the activity of glycosyltransferases at specific sequons.

ASSOCIATED CONTENT

Supporting Information

Supplemental Figure 1: Reduced and permethylated N-glycans from haptoglobin, hemopexin, and complement factor H were profiled using MALDI-ToF. Supplemental Table 1: List of glycan compositions observed in MALDI-ToF analysis of reduced and permethylated N-glycans from haptoglobin, hemopexin, and complement factor H with their relative distribution. Supplemental Figure 2: Detailed structure of haptoglobin N-glycans m/z 1246, showing a mixture of isomers, including Lewis X, H2, and Lewis Y epitopes. Supplemental Figure 3: Detailed analysis of biantennary monosialylated, monofucosylated N-glycan from complement factor H. Supplemental Figure 4: Detailed analysis of biantennary monosialylated, monofucosylated N-glycan from hemopexin. Supplemental Figure 5: Structures of the B-type fragment ions for Lewis X, H2, and Lewis Y with diagnostically important fragment ions assigned. Peak lists for MS mass spectra. This material is available free of charge via the Internet at http://pubs.acs.org.

AUTHOR INFORMATION

Corresponding Author

*Tel: 202-687-9868. Fax: 202-687-1988. E-mail: rg26@georgetown.edu.

Notes

The authors declare no competing financial interest.
ACKNOWLEDGMENTS

This work was supported by NCI’s U01 CA168926 and RO1 CA135069 awarded to R.G. and CCSG Grant P30 CA51008 (to Lombardi Comprehensive Cancer Center supporting the Proteomics and Metabolomics Shared Resource). P.P. was supported by AMVIS Czech Republic-U.S. exchange program LH13051 and by Grant Agency of the Czech Republic (Grant P206/12/0503), Charles University (ProjectUNCE_204025/2012). D.J.A. was supported by a partnership arrangement between the The UNH Glycomics Center and Glycan Connections, LLC, Lee, NH.

REFERENCES

(1) Kornfeld, R.; Kornfeld, S. Assembly of asparagine-linked oligosaccharides. Ann. Rev. Biochem. 1985, 54, 631–664.
(2) Roth, J.; Taatjes, D.; Lucocq, J. M.; Weinstein, J.; Paulson, J. C. Demonstration of an extensive trans-tubular network continuous with the Golgi apparatus stack that may function in glycosylation. Cell 1985, 43 (1), 287–295.
(3) Lai, J. E.; Hennisset, B.; Davies, G. J.; Withers, S. G. Glycosyltransferases: structures, functions, and mechanisms. Ann. Rev. Biochem. 2008, 77, 521–555.
(4) West, M. B.; Segu, Z. M.; Feasley, C. L.; Sun, B. M.; Horsmans, Y.; Dell, A.; Haslam, D. J.; Abrahams, J. A.; Kim, Y. G.; Henry, G. W.; Shadick, N. A.; Weinblatt, M. E.; Rudd, P. M.; Dwek, R. A. HPLC-based reversed-phase liquid chromatography-mass spectrometry of proton adducts of fucosylated N-glycans: fucose transfer between antennae gives rise to misleading fragments. J. Am. Soc. Mass Spectrom. 2014, 13, 5561–5569.
(5) Miyoshi, E.; Nakano, M. Fucosylated haptoglobin is a novel marker for pancreatic cancer: detailed analyses of oligosaccharide structures. Proteomics 2008, 8 (16), 3257–3262.
(6) Anderson, N.; Pollacci, A.; Hayes, P.; Sterapondos, G.; Newsome, P.; Boyer, A.; Smith, K. A preliminary evaluation of the differences in the glycosylation of alpha-1-acid glycoprotein between individual liver diseases. Biomed. Chromatogr. 2002, 16 (6), 365–372.
(7) Miyoshi, E.; Nakano, M. Fucosylated haptoglobin is a novel marker for colorectal cancer: implications for a biomarker of hepatocellular carcinoma. J. Proteome Res. 2010, 9, 215.
(8) Comunale, M. A.; Lee, D. M.; Rudd, P. M.; Dwek, R. A. Semi-automated identification of N-Glycopeptides by hydrophilic interaction chromatography, nano-reverse-phase LC-MS/MS, and glycain database search. J. Proteome. Res. 2012, 11 (3), 1728–1740.
(9) Bones, J.; Byrne, J. C.; O’Donoghue, N.; McManus, C.; Scaife, C.; Boissin, H.; Nastase, A.; Rudd, P. M. Glycomic and glycoproteomic analysis of serum from patients with stomach cancer reveals potential markers arising from host defense response mechanisms. J. Proteome. Res. 2011, 10 (3), 1246–1265.
(10) Ashline, D. J.; Hanneman, A. J.; Zhang, H.; Reinhold, V. N. Structural documentation of glycain epitopes: sequential mass spectrometry and spectral matching. J. Am. Soc. Mass Spectrom. 2014, 25 (3), 444–453.
(11) Miyoshi, E.; Nakano, M. Fucosylated haptoglobin is a novel marker for pancreatic cancer: detailed analyses of oligosaccharide structures. Proteomics 2008, 8 (16), 3257–3262.
(12) Anderson, N.; Pollacci, A.; Hayes, P.; Sterapondos, G.; Newsome, P.; Boyer, A.; Smith, K. A preliminary evaluation of the differences in the glycosylation of alpha-1-acid glycoprotein between individual liver diseases. Biomed. Chromatogr. 2002, 16 (6), 365–372.
(13) Miyoshi, E.; Nakano, M. Fucosylated haptoglobin is a novel marker for colorectal cancer: implications for a biomarker of hepatocellular carcinoma. J. Proteome Res. 2010, 9, 215.
(14) Debruyne, E. N.; Vanderschaeghe, D.; Van, V. H.; Vanhecke, A.; Callewaert, N.; Delanghe, J. R. Diagnostic value of the hemepxin N-glycan profile in hepatocellular carcinoma patients. Physiol. Rev. 2010, 90 (5), 823–831.
(15) Miyoshi, E.; Nakano, M. Fucosylated haptoglobin is a novel marker for colorectal cancer: implications for a biomarker of hepatocellular carcinoma. J. Proteome Res. 2010, 9, 215.
(31) Lottspeich, F.; Kellermann, J.; Henschen, A.; Foertsch, B.; Muller-Esterl, W. The amino acid sequence of the light chain of human high-molecular-mass kininogen. *Eur. J. Biochem.* 1985, 152 (2), 307–314.

(32) Dempsey, E.; Rudd, P. M. Acute phase glycoproteins: bystanders or participants in carcinogenesis? *Ann. N.Y. Acad. Sci.* 2012, 1253, 122–132.

(33) Whaley, K.; Ruddy, S. Modulation of the alternative complement pathways by beta 1 H globulin. *J. Exp. Med.* 1976, 144 (5), 1147–1163.

(34) Ripoche, J.; Day, A. J.; Harris, T. J.; Sim, R. B. The complete amino acid sequence of human complement factor H. *Biochem. J.* 1988, 249 (2), 593–602.

(35) Aebi, M. N-linked protein glycosylation in the ER. *Biochim. Biophys. Acta* 2013, 1833 (11), 2430–2437.

(36) Parodi, A. J. Protein glucosylation and its role in protein folding. *Annu. Rev. Biochem.* 2000, 69, 69–93.

(37) Thaysen-Andersen, M.; Packer, N. H. Site-specific glycoproteo-mics confirms that protein structure dictates formation of N-glycan type, core fucosylation and branching. *Glycobiology* 2012, 22 (11), 1440–1452.